After investigators selected chemotherapy ( pegylated liposomal doxorubicin , weekly paclitaxel , or topotecan ) , patients were randomly assigned to single-agent chemotherapy alone or with bevacizumab ( 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks ) until progression , unacceptable toxicity , or consent withdrawal .